Refine
Has Fulltext
- yes (45)
Is part of the Bibliography
- yes (45)
Year of publication
- 2020 (45) (remove)
Document Type
- Journal article (32)
- Doctoral Thesis (13)
Keywords
- Neuropathischer Schmerz (3)
- Parkinson-Krankheit (3)
- multiple sclerosis (3)
- small fiber neuropathy (3)
- Fabry disease (2)
- Polyneuropathie (2)
- Proprioception (2)
- autoimmune (2)
- brain (2)
- criteria (2)
- fibromyalgia syndrome (2)
- gait initiation (2)
- glial fate modulation (2)
- mortality (2)
- myelin (2)
- neurology (2)
- pain (2)
- transplantation (2)
- ALS mimic (1)
- Adaptive cell transfer (1)
- Age (1)
- Alter (1)
- Amplitude (1)
- Aneurysma (1)
- Autoimmun (1)
- Axon degeneration (1)
- Biomarker (1)
- Biopsie (1)
- C-reactive protein (1)
- CCS (1)
- Charcot–Marie–Tooth disease type 1A (1)
- Corneale confocale Mikroskopie (1)
- Cytokine (1)
- DYT1 (1)
- Donor lymphocytes (1)
- Dopamine (1)
- ET (1)
- El Escorial (1)
- Encephalitis (1)
- English version (1)
- Enzephalitis (1)
- Essentieller Tremor (1)
- Evoziertes Potenzial (1)
- F-18-FDG PET (1)
- Fabry genotype (1)
- Fabry phenotype (1)
- Fabry-associated pain (1)
- Fatigue (1)
- Gait initiation (1)
- Genetik (1)
- Genexpression (1)
- Guillain-Barre-Syndrome (1)
- Haut (1)
- Hautstanzbiopsie (1)
- IL-22 binding protein isoform (1)
- IL-4 (1)
- IL22RA2 (1)
- Intraepidermale Nervenfaserdichte (1)
- JCV (1)
- Konfokale Mikroskopie (1)
- LSVT-big therapy (1)
- Langerhans cells (1)
- Macrophages (1)
- Merkel cell density (1)
- Microglia (1)
- Mikroneurographie (1)
- Motor Control (1)
- Multiple Sklerose (1)
- Musikwahrnehmung (1)
- Myeloma (1)
- NETs (1)
- Nervenfaser (1)
- Neurodegeneration (1)
- Neuronal ceroid lipofuscinosis (1)
- Nicht-motorische Begleitsymptome (1)
- PET (1)
- PML (1)
- PNP (1)
- Pain questionnaire (1)
- Parkinson (1)
- Parkinson disease (1)
- Parkinson's Disease (1)
- Parkinson’s disease (1)
- Parkionson's disease (1)
- Pathomechanismus (1)
- Pointing error (1)
- Polyneuropathy (1)
- Prodigy (1)
- Propriozeption (1)
- Psychophysik (1)
- Quantitative sensorische Testung (1)
- Quantitativer sudomotorischer Axonreflextest (1)
- Rhythmusperzeption (1)
- STDT (1)
- Schmerz-assoziierte evozierte Potenziale (1)
- Sensorik <Neurophysiologie> (1)
- Small Fiber Neuropathie (1)
- Stiff-Person-Syndrom (1)
- Subarachnoidalblutung (1)
- T lymphocytes (1)
- TDMT (1)
- TIMP-1 (1)
- TOR1A (1)
- Tdp-43 (1)
- Temporal Discrimination Threshold (1)
- Training (1)
- Zeitwahrnehmung (1)
- accuracy (1)
- acute ischemic stroke (1)
- acute lymphoblastic leukaemia (1)
- alpha-synuclein (1)
- amyotrophic lateral sclerosis (1)
- anthropometric measurements (1)
- anti-Amphiphysin Antikörper (1)
- anti-amphiphysin antibodies (1)
- areas (1)
- autoantibodies (1)
- axon guidance molecules (1)
- axonal transcriptome (1)
- back pain (1)
- basal ganglia (1)
- base of support (1)
- behavioral disorders (1)
- binding (1)
- biomarker (1)
- biopsies (1)
- blood sedimentation (1)
- brain metabolic alterations (1)
- brain stem (1)
- care tempis (1)
- cerebellar tDCS (1)
- cerebellar vermis hypoplasia (1)
- cerebellum (1)
- children (1)
- circuitopathies (1)
- classification (1)
- clinical diagnosis (1)
- compensatory strategies (1)
- consolidation (1)
- corneal confocal microscopy (1)
- cutaneous innervation (1)
- cytokines (1)
- dementia (1)
- diagnosis (1)
- disease (1)
- dopamine (1)
- dystonia (1)
- epidermis (1)
- exercise (1)
- expression (1)
- fatigue (1)
- freezing of gait (1)
- fungal infection (1)
- galactomannan (1)
- gene expression (1)
- generalized cerebellar atrophy (1)
- giant cell arteritis (1)
- glycine receptor autoantibodies (1)
- guidelines (1)
- health behavior (1)
- hemoglobin (1)
- high contrast (1)
- hospitals (1)
- human neurons (1)
- immunohistochemistry (1)
- incidence (1)
- induced neural stem cells (1)
- inducible expression (1)
- infarction volume (1)
- inflammatory demyelinating polyradiculoneuropathy (1)
- internet-based intervention (1)
- intraepidermal nerve fibre density (1)
- ischemic stroke (1)
- just noticeable difference (JND) (1)
- locomotor adaptation (1)
- lyso‐Gb3 (1)
- mesenchymal stem cells (1)
- miRNA (1)
- miRNS (1)
- microRNA (1)
- motor neuron disease (1)
- muscle atrophy (1)
- musical syntax (1)
- musikalische Syntax (1)
- musk myasthenia gravis (1)
- mutation (1)
- nerve-fibers (1)
- neural stem cell (1)
- neural stem cells (1)
- neuroborreliosis (1)
- neurofascin (1)
- neuronal differentiation (1)
- neuronal stem cells (1)
- neuropathic pain (1)
- neutrophils (1)
- nicotinamide (1)
- oligodendroglia (1)
- online systems (1)
- ontactin 1 (1)
- opioid (1)
- opioids (1)
- outcomes (1)
- p57kip2 (1)
- parkinson's disease (1)
- pathophysilogical mechanisms (1)
- periperal nerve (1)
- physical activity (1)
- pilot project (1)
- postural control (1)
- progressive ataxia (1)
- psychophysics (1)
- quality (1)
- quality of life (1)
- regional heterogeneity (1)
- rehabilitation (1)
- reinnervation (1)
- reproducible outcome measure (1)
- resting tremor (1)
- rhythmperception (1)
- risk (1)
- secretome (1)
- siRNA (1)
- signal peptide (1)
- skin biopsy (1)
- skin cells (1)
- skin punch biopsy (1)
- small molecule (1)
- small-molecule Inhibitoren (1)
- small-molecule inhibitors (1)
- spinal cord (1)
- spinal cord injury (1)
- split-belt treadmill (1)
- stenosis (1)
- stimulation (1)
- stroke (1)
- substance-P (1)
- switch (1)
- synapse (1)
- synaptic vesicles (1)
- systematic review (1)
- thrombemboli (1)
- thrombolysis (1)
- time (1)
- time perception (1)
- torsinA (1)
- transmission electron microscopy (1)
- vertebrobasilar insufficiency (1)
- vertebrobasilar stroke (1)
- vertigo (1)
- walking (1)
- zeitliche Wahrnehmungsschwellen (1)
- α‐GalA 3D‐structure (1)
Institute
- Neurologische Klinik und Poliklinik (45) (remove)
Sonstige beteiligte Institutionen
The pathophysiological mechanisms of pain in small fiber neuropathy (SFN) are unclear. Based on experimental and clinical studies, sensitized nociceptors in the skin are reported to be involved in pain development. These nociceptors may be sensitized by cutaneous and systemic pain mediators e.g. pro- and anti-inflammatory cytokines. The aim of our study was, to measure the systemic and local gene expression of pro- and anti-inflammatory cytokines in white blood cells (WBC) as well as in primary fibroblasts and keratinocytes obtained from human skin of patients with SFN. Furthermore, gene expression levels of axon guidance molecules and their receptors, as potential regulators of the intraepidermal nerve fiber density (IENFD), were investigated. 55 patients and 31 healthy controls were prospectively recruited. Participants underwent extensive clinical phenotyping and blood sampling, 6-mm skin punch biopsies were taken from the right lateral calf and the upper thigh. Systemic relative gene expression levels (ΔG) of the interleukin (IL)-1β, IL-2, IL-6, IL-8, and tumor necrosis factor (TNF) was measured in WBC. Skin punch biopsies were taken to determine the IENFD and to obtain primary fibroblast and keratinocyte cell cultures. Skin cells were then used for investigation of ΔG in axon guidance molecules netrin 1 (NTN1) and ephrin A4 (EPHA4) as well as their receptors Unc5b receptor, and ephrin A4 (EFNA4) as well as cytokines IL-1β, IL-4, IL-6, IL-8, IL-10, TNF, and transforming growth factor (TGF). Systemically, gene expression of IL-2, IL-8, and TNF was higher in SFN patients compared to healthy controls. In keratinocytes, higher expression levels of NTN1 and TGF were found when comparing the SFN patients to the controls. In fibroblasts higher gene expression was shown in NTN1, Unc5b, IL-6, and IL-8 when comparing patients to healthy controls. The systemically and local elevated levels of pro-inflammatory, algesic cytokines in SFN patients compared to healthy controls, confirms a potential pathophysiological role in the development of neuropathic pain. Data also indicate fibroblasts and keratinocytes to influence subepidermal and intraepidermal nerve fiber growth through the expression of NTN1 and Unc5b. Thus, skin cells may contribute to the development of neuropathic pain through local denervation.
Zeitliche Diskrimination somatosensorischer und kinästhetischer Stimuli wurde als neurophysiologisches Korrelat für propriozeptive Präzision postuliert und bei verschiedenen Bewegungsstörungen als pathologisch beschrieben. Ziel der Untersuchung war es, den Einfluss von Alter und Polyneuropathie auf die kinästhetische (TDMT) und taktile (STDT) zeitliche Wahrnehmungsschwelle sowie die propriozeptive Genauigkeit bei Zeigeversuchen systematisch zu untersuchen.
Hierfür wurden 54 gesunde Probanden und 25 Polyneuropathie-Patienten im Alter zwischen 30 und 76 Jahren untersucht. Die STDT-Messung erfolgte mit Oberflächenelektroden, die an der Zeigefingerspitze bzw. am Großzehengrundgelenk angebracht wurden. Die TDMT-Werte wurden mit Hilfe einer sterilen Nadelelektrode erfasst, welche in den Musculus flexor carpi radialis bzw. Musculus tibialis anterior inseriert wurde.
Die Daten zur Propriozeption wurden mit Hilfe eines Goniometers erhoben und beinhalteten dabei aktive Zeigeaufgaben (Zeigen auf eine LED, Nachahmung einer Bewegung anhand einer auf einem Computerbildschirm dargebotenen PFEIL-Darstellung unterschiedlicher Länge) und die Einschätzung der Position der jeweiligen Extremität nach passiver Bewegung (PASSIV). Die Messungen erfolgten jeweils ohne visuelle Rückmeldung. Die Zeigefehler (Abweichung von der Zielposition) bzw. Schätzfehler (Abweichung der geschätzten von der tatsächlichen Position nach passiver Auslenkung) wurden als Maß der propriozeptiven Präzision verwendet.
Die Ergebnisse der gesunden Probandengruppe zeigten, dass höheres Alter mit höheren STDT- und TDMT-Werten korrelierte. Die Polyneuropathie-Patienten erzielten in allen Bereichen (Diskriminationsschwellen und Propriozeptionsaufgaben) signifikant schlechtere Ergebnisse als die gesunde Kontrollgruppe.
Zusätzlich konnte eine statistisch signifikante positive Korrelation zwischen der propriozeptiven Präzision bei den aktiven Zeige-Aufgaben (LED und PFEIL) und den zeitlichen Diskriminationsschwellen (STDT und TDMT) gezeigt werden.
In Anbetracht dieser Ergebnisse sollten das Patienten-Alter und mögliche Störungen der peripheren Nervenleitung berücksichtigt werden, wenn STDT-und TDMT-Bestimmungen bei Patienten mit Bewegungsstörungen angewendet werden. Die Korrelation zwischen den Diskriminationsschwellen und der Performance bei aktiven Zeigeversuchen (PFEIL- und LED-Aufgabe) legt nahe, dass STDT und TDMT Indikatoren der propriozeptiven Funktion sein könnten. Es ist weitere Forschungsarbeit notwendig, um diese Beziehung exakt zu beleuchten. Im Falle einer Bestätigung der Befunde auch bei Patienten mit Bewegungsstörungen erscheint denkbar, dass sich STDT und TDMT als vergleichsweise leicht messbare und gut quantifizierbare Parameter der Propriozeption herausstellen mit Potenzial zur differenzialdiagnostischen Anwendung, möglicherweise aber auch als Surrogatparameter einer gezielten rehabilitativen Behandlung.
In dieser Arbeit wurde mit Hilfe von small-molecule Inhibitoren die Rolle von clathrin- und dynaminabhängigen Endozytosemechanismen bei der Aufnahme von anti-Amphiphysin-Autoantikörpern am Zellkulturmodell primärer hippocampaler Neurone untersucht. Hierbei konnte eine Beeinflussung der Autoaantikörperaufnahme durch die Intervention gezeigt werden. Außerdem erfolgte der Versuch der Etablierung eines siRNA knockdowns unter Zuhilfenahme unterschiedlicher Traansfektionsreaaagenzien.
Deterioration of gait and alterations of physiological gait initiation contribute significantly to the burden of disease in Parkinson's disease. This paper systematically investigates disease-specific alterations during the postural phases of gait initiation and demonstrates the influence of dopaminergic networks by assessing levodopa mediated improvements in motor performance and correlation of motor behavior with loss of striatal and cortical dopaminergic neurons. Particular attention is given to known confounders such as initial stance and anthropometrics.
Der essentielle Tremor (ET) ist eine der häufigsten Bewegungsstörungen, welcher lange Zeit als rein motorische Störung angesehen wurde. Aufgrund zunehmender Belege über nicht-motorisch Begleitsymptome wandelte sich dieses Bild jedoch in den letzten Jahren zunehmend. In der vorliegenden Arbeit untersuchten wir 113 Probanden aus der Allgemeinbevölkerung mit klinisch definitiven oder wahrscheinlichen ET anhand einer breiten Batterie neuro-psychologischer Testverfahren. Es gelang hierbei signifikante Unterschiede im Vergleich zu gesunden Eichstichproben im Hinblick auf neuro-psychologische Charakteristika, wie Apathie, Ängstlichkeit und exekutive Dysfunktion, sowie deren negativen Einfluss auf die Lebensqualität der Probanden darzustellen. Bisher werden im klinischen Alltag nicht-motorische Begleitphänomene beim ET nicht regelhaft erfasst; aufgrund unserer Ergebnisse und der Relevanz vor allem im Hinblick auf die Lebensqualität des Einzelnen halten wir jedoch die Erfassung und gegebenenfalls Behandlung dieser Symptome für ebenso relevant.
microRNA-Genexpressionsprofile in Blut-, Haut- und Nervenproben von Patienten mit Polyneuropathien
(2020)
Die Polyneuropathie (PNP) ist die häufigste Störung des peripheren Nervensystems bei Erwachsenen. Die Suche nach der Ursache bleibt in vielen Fällen erfolglos, ist aber unverzichtbar, da die Therapiewahl von der Ätiologie der Erkrankung abhängt. Geeignete Biomarker könnten die Differentialdiagnose unter Umständen erleichtern. microRNAs (miRNAs) sind in dieser Hinsicht vielversprechend, da in vielen Studien bei Nervende- und regenerationsprozessen sowie in neuropathischen Schmerzmodellen eine Dysregulation beschrieben wurde.
In dieser Studie wurde die Expression zweier miRNAs, miR-103a und miR-let-7d, sowie eines Zielmoleküls der miR-103a, des Kalziumkanals Cav1,2, in einer großen Kohorte von PNP-Patienten unterschiedlicher Ätiologie in Blut, Haut- und Nervenbiopsien untersucht. Insgesamt wurden 116 Patienten und 22 Kontroll-probanden in die Studie eingeschlossen. Nach der Isolation von RNA aus weißen Blutzellen (WBC), Haut- und Nervenbiopsien folgte die Expressionsbestimmung mittels qRT-PCR.
Während sich jeweils Unterschiede zwischen PNP-Patienten und Kontrollen und zwischen Patienten mit entzündlicher und solchen mit nicht-entzündlicher PNP zeigten, wurden keine Unterschiede in der Expression zwischen den ätiologischen Subgruppen oder zwischen Patienten mit schmerzhafter und schmerzloser PNP festgestellt. In den Nervenbiopsien der Patientenkohorte ergab sich eine inverse Korrelation der miR-103a und ihrem Zielgen Cacna1c, die darauf hinweisen könnte, dass Cacna1c von der miR-103a negativ reguliert wird.
Da in unserer Patientenkohorte keine Unterschiede zwischen den PNP-Subgruppen auftraten, scheint der Einsatz der miR-103a und miR-let-7d als diagnostische Biomarker zur ätiologischen Einordnung einer PNP nicht gerechtfertigt. Dennoch deuten unsere Ergebnisse auf eine mögliche Rolle der untersuchten miRNAs bei Entstehung und Verlauf von PNP hin. Für ein tieferes pathophysiologisches Verständnis der miRNAs vor allem bei entzündlichen Neuropathien, könnte die Untersuchung von weiteren miRNAs und Zielgenen Aufschluss geben.
Parkinson’s disease (PD) is among the most common neurodegenerative conditions, and it is characterized by the progressive loss of dopaminergic neurons and a great variability in clinical expression. Despite several effective medications, it still causes disability as all patients show treatment-resistant symptoms and complications.
A possible reason for this therapeutic-burden and great clinical variability lies in a probable misconception about its pathophysiology, one that focuses on neurodegeneration, while largely neglecting its functional consequences and the related compensatory changes. In this thesis, I expand on the hypothesis that some PD symptoms have a dysfunctional origin and reflect derangements of neural network dynamics, the means by which brain coordination supports any motor behaviour. In particular, I have investigated resting tremor and freezing of gait, two common symptoms with an enigmatic mechanism and suboptimal management.
In the case of tremor, I predicted a pathological change in response to dopamine loss, which included the activation of noradrenergic (NA) neurons of the locus coeruleus (LC) projecting to the cerebellum. This compensatory LC activation that supports dopaminergic neurons might indeed come at the expense of tremor development. To assess the role of LC-NA in tremor development, I recorded tremor occurrence in the reserpinized rat model of PD, one of very few showing tremor, after selective lesioning (with the neurotoxin DSP-4) of the LC-NA terminal axons. DSP-4 induced a severe reduction of LC-NA terminal axons in the cerebellar cortex and this was associated with a significant reduction in tremor development. Unlike its development, tremor frequency and the akinetic rigid signs did not differ between the groups, thus suggesting a dopaminergic dependency. These findings suggest that the LC-NA innervation of the cerebellum has a critical role for PD tremor, possibly by exerting a network effect, which gates the cerebello-thalamic-cortical circuit into pathological oscillations upon a dopaminergic loss in the basal ganglia.
In contrast, for the study of freezing of gait, I worked with human PD subjects and deep brain stimulation, a therapeutic neuromodulation device that in some prototypes also allows the recording of neural activity in freely-moving subjects. Gait freezing is a disabling PD symptom that suddenly impairs effective stepping, thus causing falls and disability. Also in this study, I hypothesized that the underlying pathophysiology may be represented by dysfunctional neural network dynamics that abruptly impair locomotor control by affecting the communication in the supraspinal locomotor network. To test this hypothesis, I investigated the coupling between the cortex and the subthalamic nucleus, two main nodes of the supraspinal locomotor network, in freely-moving subjects PD patients and also performed molecular brain imaging of striatal dopamine receptor density and kinematic measurements. I found that in PD patients, walking is associated with cortical-subthalamic stable coupling in a low-frequency band (i.e. θ-α rhythms). In contrast, these structures decoupled when gait freezing occurred in the brain hemisphere with less dopaminergic innervation. These findings suggest that freezing of gait is a “circuitopathy”, with dysfunctional cortical-subcortical communication.
Altogether the results of my experiments support the hypothesis that the pathophysiology of PD goes beyond neurodegenerative (loss-of-function) processes and that derangement of neural network dynamics coincides with some disabling PD symptoms, thus suggesting that PD can be interpreted as the combination of multiple circuitopathies.
Protein inclusions containing the RNA-binding protein TDP-43 are a pathological hallmark of amyotrophic lateral sclerosis and other neurodegenerative disorders. The loss of TDP-43 function that is associated with these inclusions affects post-transcriptional processing of RNAs in multiple ways including pre-mRNA splicing, nucleocytoplasmic transport, modulation of mRNA stability and translation. In contrast, less is known about the role of TDP-43 in axonal RNA metabolism in motoneurons. Here we show that depletion of Tdp-43 in primary motoneurons affects axon growth. This defect is accompanied by subcellular transcriptome alterations in the axonal and somatodendritic compartment. The axonal localization of transcripts encoding components of the cytoskeleton, the translational machinery and transcripts involved in mitochondrial energy metabolism were particularly affected by loss of Tdp-43. Accordingly, we observed reduced protein synthesis and disturbed mitochondrial functions in axons of Tdp-43-depleted motoneurons. Treatment with nicotinamide rescued the axon growth defect associated with loss of Tdp-43. These results show that Tdp-43 depletion in motoneurons affects several pathways integral to axon health indicating that loss of TDP-43 function could thus make a major contribution to axonal pathomechanisms in ALS.
Objective
Impairment of glycinergic neurotransmission leads to complex movement and behavioral disorders. Patients harboring glycine receptor autoantibodies suffer from stiff‐person syndrome or its severe variant progressive encephalomyelitis with rigidity and myoclonus. Enhanced receptor internalization was proposed as the common molecular mechanism upon autoantibody binding. Although functional impairment of glycine receptors following autoantibody binding has recently been investigated, it is still incompletely understood.
Methods
A cell‐based assay was used for positive sample evaluation. Glycine receptor function was assessed by electrophysiological recordings and radioligand binding assays. The in vivo passive transfer of patient autoantibodies was done using the zebrafish animal model.
Results
Glycine receptor function as assessed by glycine dose–response curves showed significantly decreased glycine potency in the presence of patient sera. Upon binding of autoantibodies from 2 patients, a decreased fraction of desensitized receptors was observed, whereas closing of the ion channel remained fast. The glycine receptor N‐terminal residues \(^{29}\)A to \(^{62}\)G were mapped as a common epitope of glycine receptor autoantibodies. An in vivo transfer into the zebrafish animal model generated a phenotype with disturbed escape behavior accompanied by a reduced number of glycine receptor clusters in the spinal cord of affected animals.
Interpretation
Autoantibodies against the extracellular domain mediate alterations of glycine receptor physiology. Moreover, our in vivo data demonstrate that the autoantibodies are a direct cause of the disease, because the transfer of human glycine receptor autoantibodies to zebrafish larvae generated impaired escape behavior in the animal model compatible with abnormal startle response in stiff‐person syndrome or progressive encephalitis with rigidity and myoclonus patients.
Objective: We investigated cerebral opioid receptor binding potential in patients with fibromyalgia syndrome (FMS) using positron-emission-tomography (PET) and correlated our results with patients’ systemic interleukin-4 (IL-4) gene expression.
Methods: In this pilot study, seven FMS patients (1 man, 6 women) agreed to participate in experimental PET scans. All patients underwent neurological examination, were investigated with questionnaires for pain, depression, and FMS symptoms. Additionally, blood for IL-4 gene expression analysis was withdrawn at two time points with a median latency of 1.3 years. Patients were investigated in a PET scanner using the opioid receptor ligand F-18-fluoro-ethyl-diprenorphine ([18F]FEDPN) and results were compared with laboratory normative values.
Results: Neurological examination was normal in all FMS patients. Reduced opioid receptor binding was found in mid cingulate cortex compared to healthy controls (p < 0.005). Interestingly, three patients with high systemic IL-4 gene expression had increased opioid receptor binding in the fronto-basal cortex compared to those with low IL-4 gene expression (p < 0.005).
Conclusion: Our data give further evidence for a reduction in cortical opioid receptor availability in FMS patients as another potential central nervous system contributor to pain in FMS.